Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2138847 | Leukemia Research | 2008 | 13 Pages |
Abstract
A series of 10 heterocyclic compounds purified from Allanblackia were tested on two B cell lines, ESKOL and EHEB, and on cells from B-CLL patients. Several molecules inhibited the proliferation of both cell lines and promoted apoptosis of B-CLL cells through different mechanisms, some of them elicited a dissipation of the mitochondrial transmembrane potential, other triggered caspase-3 activation and cleavage of the inducible nitric oxide synthase. Blood mononuclear cells and B-lymphocytes from healthy donors appeared less sensitive than B-CLL cells. These results indicate that these molecules may be of interest in the development of new therapies for B-CLL.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
F. Menasria, A.G.B. Azebaze, C. Billard, A.M. Faussat, A.E. Nkengfack, M. Meyer, J.P. Kolb,